Apr 16, 2010 9:35am EDT SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class
Apr 15, 2010 12:01pm EDT SCYNEXIS' SCY-635 Demonstrates Impressive Barrier to Resistance in HCV Treatment
Apr 05, 2010 9:35am EDT SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver
Dec 17, 2009 8:00am EST SCYNEXIS, Inc. Receives Milestone Payment From Collaboration With Merck & Co., Inc.
Nov 03, 2009 8:03am EST SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
Oct 28, 2009 2:59pm EDT SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting
Oct 27, 2009 8:00am EDT SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.
